The effects of Lyprinol ® on delayed onset muscle soreness and muscle damage in well trained athletes: A double-blind randomised controlled trial

Kate Pumpa, Kieran E. Fallon, Alan Bensoussan, Shona Papalia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives

The aim of the study was to determine if Lyprinol® is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).

Design

A double blind randomised placebo controlled trial.

Setting

Twenty well trained male volunteers, matched by VO2 max were randomly assigned to consume 200 mg of Lyprinol® or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.

Main outcome measures

Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run).

Results

No statistically significant differences were identified in any parameters between the active and placebo groups at any time point.

Conclusion

After 2 months ingestion of Lyprinol® at the currently recommended dosage (200 mg/day) and a demanding eccentric exercise intervention, Lyprinol® did not convincingly affect DOMS and indicators of muscle damage.
Original languageEnglish
Pages (from-to)311-318
Number of pages8
JournalComplementary Therapies in Medicine
Volume19
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Myalgia
Athletes
Randomized Controlled Trials
Muscles
Placebos
Lymphotoxin-beta
Myoglobin
Pain Measurement
Creatine Kinase
Visual Analog Scale
Interleukin-1
Running
Interleukin-10
C-Reactive Protein
Volunteers
Interleukin-6
Eating
Outcome Assessment (Health Care)
Exercise
Inflammation

Cite this

@article{a8a794bc57a94415ad2ce45eb1c2b252,
title = "The effects of Lyprinol {\^A}{\circledR} on delayed onset muscle soreness and muscle damage in well trained athletes: A double-blind randomised controlled trial",
abstract = "ObjectivesThe aim of the study was to determine if Lyprinol{\circledR} is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).DesignA double blind randomised placebo controlled trial.SettingTwenty well trained male volunteers, matched by VO2 max were randomly assigned to consume 200 mg of Lyprinol{\circledR} or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.Main outcome measuresPerformance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run).ResultsNo statistically significant differences were identified in any parameters between the active and placebo groups at any time point.ConclusionAfter 2 months ingestion of Lyprinol{\circledR} at the currently recommended dosage (200 mg/day) and a demanding eccentric exercise intervention, Lyprinol{\circledR} did not convincingly affect DOMS and indicators of muscle damage.",
author = "Kate Pumpa and Fallon, {Kieran E.} and Alan Bensoussan and Shona Papalia",
year = "2011",
doi = "10.1016/J.CTIM.2011.08.004",
language = "English",
volume = "19",
pages = "311--318",
journal = "Complementary Medical Research",
issn = "0965-2299",
publisher = "Churchill Livingstone",
number = "6",

}

The effects of Lyprinol ® on delayed onset muscle soreness and muscle damage in well trained athletes: A double-blind randomised controlled trial. / Pumpa, Kate; Fallon, Kieran E.; Bensoussan, Alan; Papalia, Shona.

In: Complementary Therapies in Medicine, Vol. 19, No. 6, 2011, p. 311-318.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of Lyprinol ® on delayed onset muscle soreness and muscle damage in well trained athletes: A double-blind randomised controlled trial

AU - Pumpa, Kate

AU - Fallon, Kieran E.

AU - Bensoussan, Alan

AU - Papalia, Shona

PY - 2011

Y1 - 2011

N2 - ObjectivesThe aim of the study was to determine if Lyprinol® is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).DesignA double blind randomised placebo controlled trial.SettingTwenty well trained male volunteers, matched by VO2 max were randomly assigned to consume 200 mg of Lyprinol® or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.Main outcome measuresPerformance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run).ResultsNo statistically significant differences were identified in any parameters between the active and placebo groups at any time point.ConclusionAfter 2 months ingestion of Lyprinol® at the currently recommended dosage (200 mg/day) and a demanding eccentric exercise intervention, Lyprinol® did not convincingly affect DOMS and indicators of muscle damage.

AB - ObjectivesThe aim of the study was to determine if Lyprinol® is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).DesignA double blind randomised placebo controlled trial.SettingTwenty well trained male volunteers, matched by VO2 max were randomly assigned to consume 200 mg of Lyprinol® or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.Main outcome measuresPerformance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run).ResultsNo statistically significant differences were identified in any parameters between the active and placebo groups at any time point.ConclusionAfter 2 months ingestion of Lyprinol® at the currently recommended dosage (200 mg/day) and a demanding eccentric exercise intervention, Lyprinol® did not convincingly affect DOMS and indicators of muscle damage.

U2 - 10.1016/J.CTIM.2011.08.004

DO - 10.1016/J.CTIM.2011.08.004

M3 - Article

VL - 19

SP - 311

EP - 318

JO - Complementary Medical Research

JF - Complementary Medical Research

SN - 0965-2299

IS - 6

ER -